Application of chimeric antigen receptor T-cell immunotherapy in primary liver cancer
10.3969/j.issn.1001-5256.2022.10.036
- VernacularTitle:嵌合抗原受体T淋巴细胞免疫疗法在原发性肝癌中的应用
- Author:
Kangwei LI
1
;
Ding WEI
2
;
Ruohan ZHANG
3
;
Xiao LI
3
;
Kaishan TAO
3
Author Information
1. Graduate School, School of Basic Medical Sciences, Fourth Military Medical University, Xi'an 710032, China
2. Department of Cell Biology, School of Basic Medical Sciences, Fourth Military Medical University, Xi'an 710032, China
3. Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China
- Publication Type:Reviews
- Keywords:
Liver Neoplasms;
Immunotherapy;
Chimeric Antigen Receptor T Cell
- From:
Journal of Clinical Hepatology
2022;38(10):2387-2390
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer has the features of high malignancy, rapid progression, frequent recurrence/metastasis, and high mortality, and therefore, most patients have developed intrahepatic or extrahepatic metastasis when attending the hospital and thus lost the opportunity for surgical treatment. Chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved good efficacy in the treatment of B-cell acute lymphoblastic leukemia, and clinical trials have been initiated to explore its applications in solid tumors such as primary liver cancer, pancreatic cancer, gastric cancer, and prostate cancer. This article reviews the efficacy of CAR-T immunotherapy in the clinical trials for primary liver cancer and discusses the difficult issues that need to be solved in clinical practice, such as the lack of suitable tumor targets, the inhibitory effect of tumor microenvironment on CAR-T cells, and the poor infiltration of CAR-T cells in tumor tissue, so as to provide a reference for related clinical studies.
